DUALIZE. LEADING THE WAY OF HIV INNOVATION

1. 1.CAHN P, MADERO JS, ARRIBAS JR, ET AL; GEMINI STUDY TEAM.. DOLUTEGRAVIR PLUS LAMIVUDINE VERSUS DOLUTEGRAVIR PLUS TENOFOVIR DISPROXIL FUMARATE/EMTRICITABINE IN ANTIRETROVIRAL-NAIVE ADULTS WITH HIV-INFECTION (GEMINI-1 AND GEMINI-2); WEEK 48 RESULTS FROM TWO MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, NON-INFERIORITY, PHASE TRIALS.. LANCET.2019;393(10167):143-155.. 2019
   Articolo scientificoLANCET.2019;393(10167):143-155.Cerca su Google Scholar
2. 2.CORDOVA E, ET AL.. DOLUTEGRAVIR/LAMIVUDINE DUAL THERAPY IN ADULTS WITH LOW CD4 COUNTS AND HIGH VIRAL LOAD: RESULTS FROM THE DOLCE PHASE 4 TRIAL.. CLIN INFECT DIS. 2025; CIAF415. 2025
   Articolo scientificoCLIN INFECT DIS. 2025; CIAF415Cerca su Google Scholar
3. 3.LOCKHART SM, CROFOOT G, DRETLER R, ET AL.. EFFICACY AND SAFETY OUTCOMES IN ADULTS INITIATING DOLUTEGRAVIR/LAMIVUDINE BY BASELINE VIRAL LOAD: 144-WEEK RESULT FROM GEMINI-1/-2 AND 48-WEEK RESULTS FROM STAT.. OPEN FORUM INFECT DIS. 2024;12(3):OFAF135. 2024
   Articolo scientificoOPEN FORUM INFECT DIS. 2024;12(3):OFAF135Leggi il PDF gratuito
4. 4.LLIBRE JM JESKE S, OYEE J, ET AL.. PATIENT-REPORTED OUTCOMES AFTER SWITCHING TO DOLUTEGRAVIR/LAMIVUDINE VERSUS CONTINUING 3-/4 DRUG REGIMENS: RESULTS FROM THE SALSA TRIAL.. AIDS BEHAV. 2024;28.. 2024
   Articolo scientificoAIDS BEHAV. 2024;28.Cerca su Google Scholar

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).